10-K · March 2, 2026
Sionna is a clinical‑stage biotech focused on directly stabilizing CFTR’s NBD1 to treat cystic fibrosis, advancing multiple small‑molecule NBD1 stabilizers (SION‑719 and SION‑451) and complementary modulators toward…
Earnings analysis · 10-Q
SION earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
Sionna Therapeutics reported a Q1 2026 net loss of $26.8 million, significantly up from a loss of $16.5 million in Q1 2025. Operating expenses surged to $29.6 million, driven by increased research and development (R&D)…
Read full summary
Sionna Therapeutics reported a Q1 2026 net loss of $26.8 million, significantly up from a loss of $16.5 million in Q1 2025. Operating expenses surged to $29.6 million, driven by increased research and development (R&D) and general administrative (G&A) expenses. The company maintains a healthy cash position of $289.9 million, expected to fund operations into 2028, but continues to face substantial cash burn as it progresses its cystic fibrosis product candidates through clinical trials.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Increased R&D Investments
R&D expenses rose to $18.96 million in Q1 2026, up from $13.67 million in Q1 2025, reflecting heightened clinical activity.
-
Significant Cash Reserves
As of March 31, 2026, cash, cash equivalents, and marketable securities stand at $289.9 million, sufficient to fund operations into 2028.
-
Rising Operating Expenses
Total operating expenses totaled $29.6 million for Q1 2026, up from $19.7 million in Q1 2025, driven by G&A costs.
-
Strong Pipeline Development
Two product candidates, SION-719 and SION-451, are advancing through clinical trials, which management cites as key growth drivers.
-
Increased Net Loss
Net loss for Q1 2026 was $26.8 million, compared to $16.5 million for Q1 2025, marking a growing financial strain.
-
Commitment to Clinical Trials
Completion of enrollment for the Phase 2a trial for SION-719 and a Phase 1 trial for SION-451 demonstrates ongoing clinical commitment.
What to watch
-
Rising Operating Costs
Total operating expenses increased by $9.94 million to $29.6 million for Q1 2026 compared to Q1 2025.
-
Dependence on Clinical Trials
No revenue generated; the company is entirely reliant on the success of ongoing clinical trials to drive future revenue.
-
Competing Products
Significant competition in the cystic fibrosis treatment space, especially from established players like Vertex Pharmaceuticals.
Management's outlook
No numeric revenue or EPS guidance provided; outlook is focused on the pipeline and funding.
Earlier filings 3
10-Q · May 12, 2025
Sionna reported a net loss of $16.5M (-$0.62 per share) for the quarter ended March 31, 2025, compared with a net loss of $11.8M (-$3.84) in Q1 2024; operating expenses rose to $19.7M from $13.1M driven by higher R&D…
10-K · March 20, 2025
Sionna is a clinical-stage biopharmaceutical company focused on NBD1-targeted CFTR stabilizers and complementary modulators to address remaining unmet need in cystic fibrosis. The company has advanced two NBD1…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.